1 / 76

Canada Dermatology Prescription Market Analysis Sample Report

Canada's dermatology prescription market is expected to grow from $459.7 Mn in 2022 to $927.4 Mn in 2030 with a CAGR of 9.2% for the year 2022-30. Rising incidences of dermatology disorders involving the skin, nails, hair, etc, and the demand for novel therapeutics for the treatment of dermatology disorders in Canada are major market drivers of the Canadian dermatology prescription market. To get a detailed report, contact us at - info@insights10.com

Insights4
Download Presentation

Canada Dermatology Prescription Market Analysis Sample Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A sample report on Canada Dermatology Prescription Market Analysis Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2023 – 2030F) www.insights10.com

  2. This report presents a strategic analysis of the Canada Dermatology Prescription Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Canada Dermatology Prescription Market, and offers unmatched value, accuracy, and expert insights.

  3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  4. Table of Content CONTENT PG. NO. 6-19 1. Dermatology Prescription Market Overview 1.1. Overview 1.2. Canada Overview 1.3. Economic Overview: Canada 1.4. Dermatology Prescription Market in Canada 1.5. Pharmaceuticals Market in Canada 1.6. Healthcare Scenario in Canada 1.7. Health Insurance Coverage: Canada 1.8. Budget of the Government for Public Insurance 1.9. Mergers and Acquisitions 20-27 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 4 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  5. Table of Content CONTENT PG. NO. 2.2. Market Segmentation 28-32 3. Market Dynamics 3.1. Market Growth Drivers 3.2. Market Restraints 33-43 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 44-49 5. Reimbursement Scenario 5.1. Reimbursement Regulation 5.2. Reimbursement Process for Diagnosis 5.3. Reimbursement Process for Treatment 50-77 6. Methodology & Scope 5 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  6. Canada Dermatology Prescription Market Analysis 1. Dermatology Prescription Market Overview

  7. 1.1 Statistics at a Glance: The Burden of Dermatology Prescription Market in the World Prevalence of Dermatology Prescription Market Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 13 Mn+ new cases of skin disease will be diagnosed every day in the world in 2023 3% more skin diseases occurs in females as compared to men in the world In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ 75% skin disease deaths worldwide are caused by malignant skin melanoma, making it the leading cause of skin disease deaths 2 Mn+ people will die from skin diseases in the world in 2023 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1.79% is the contribution of skin diseases to the global burden of diseases $23 Bn+ is the projected global sales figure for skin disease drugs in the dermatology market by 2024 7 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  8. 1.1 Statistics at a Glance: The Burden of Dermatology Prescription Market in the World (continued) Europe ~Revenue to reach $xx Bn by 2027 Asia -Fastest CAGR North America ~ Market Size of $xx Bn Africa ~Market Size of $xxBn Canada Market ~$xx Mn Market 8 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  9. 1.2 Canada Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 38.85 Mn is the population of Canada, in 2022 2.14 Tn is the Gross Domestic Product (GDP) of Canada in 2021 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 41 is the median age in Canada, in 2022 $8.56 k per capita was the amount of national health expenditures in Canada, 2022 9 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  10. 1.3 Economic Overview: Canada Population of Canada , (2020-2030) GDP of Canada , (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 10 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  11. 1.4 Statistics at a Glance: The Burden of Dermatology Prescription Market in Canada Prevalence of Dermatology Prescription Market Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 1,300+ new cases of skin disease will be diagnosed every day in Canada in 2023 10% more skin diseases occurs in females as compared to men in Canada In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in Canada ▪ 8.7 k+ canadians are expected to die from skin cancer in 2023 50% skin disease deaths in Canada are caused by malignant skin melanoma, making it the leading cause of skin disease deaths In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 4.5% is the prevalence of skin disease in Canada $145 Mn+ dermatological prescription dispensed in Canada in 2023 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 11 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  12. 1.5 Pharmaceuticals in Canada Canada Pharmaceuticals Market Forecast, 2022-2030 (in $Bn) 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the overall Pharmaceuticals market in Canada , which includes the market size, current trends and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 12 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  13. 1.6 Healthcare Scenario in Canada Cancer Drug Development Process: The process of developing a cancer drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market o o o o o FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means FDA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 13 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  14. 1.6 Healthcare Scenario: Dermatology Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron status, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke Initial Diagnosis Imaging (confirm bone related changes or respiratory problems) A suspected diagnosis is usually made, based on physical examination and detailed patient and family history Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) Prevention and management of complications: Genetic testing (detect the type of SCD) • Stroke: Chronic transfusions, HU Stakeholders PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist Depending on the organ complications, the treatment involves different specialists at different times Illustrative Illustrative 14 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  15. 1.7 Health Insurance Coverage: Canada % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage Coverage Type 2020 2021 Change % 8.3 Uninsured Total 327,521 328,074 91.7 With health insurance Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 66.0 Any private plan Employment-based 178,737 178,285 –0.2 54.3 Employment-based Direct-purchase 33,869 33,555 –0.1 10.2 Direct-purchase Marketplace coverage 10,924 11,389 0.1 3.5 Marketplace TRICARE 9,165 8,299 –0.3 2.5 TRICARE Any public plan 112,925 117,095 1.2 58,541 60,226 0.5 35.7 Any public plan 18.4 58,778 61,940 0.9 18.9 VA and CHAMPVA 2,967 3,151 0.1 1.0 VA and CHAMPVA Uninsured 28,291 27,187 –0.4 In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year More people had private health insurance (66%) than public coverage (35.7%) Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) ▪ ▪ ▪ Illustrative Illustrative 15 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  16. 1.8 Budget of Canada Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 Public In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Private 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% Public As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% Private National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Public health Insurance spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 16 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  17. 1.9 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 17 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  18. 1.9 Mergers and Acquisitions (continued) Latest Deals In Canada Amount / Duration Company Name Type Year Key Pointers Oracle’s acquisition of Cerner is big tech’s latest foray into the healthcare system, promising better outcomes Oracle acquire Cerner through an all-cash tender offer for $95.00 per share, or approximately $28.3 Bn in equity value Cerner is a leading provider of digital information systems used within hospitals and health systems to enable medical professionals to deliver better healthcare to individual patients and communities ▪ ▪ Acquisition $28.3 Bn June, 2022 ▪ Oracle acquisition of Cerner GSK has acquire BELLUS for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion ▪ BELLUS is a late-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough ▪ Acquisition $2 Bn April 2023 Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough ▪ GSK acquisition of BELLUS Health Illustrative Illustrative 18 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  19. 1.9 Mergers and Acquisitions (continued) Latest Deals In Canada Amount / Duration Company Name Type Year Key Pointers Merger March 2023 Merger Jan 2023 Illustrative Illustrative 19 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  20. Canada Dermatology Prescription Market Analysis 2. Market Size and Forecasting

  21. 2.1 Market size and forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption Canada Dermatology Prescription Market Forecast, 2022-2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Healthcare Insurance market in Malaysia, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Canada Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative ▪ % of Canadian Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Canada Market Size (Bn $) 61 74 84 87 91 95 99 106 21 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  22. 2.2 Snapshot of Dermatology Prescription Market Segmentation Route of Administration Distribution Channels Disease Drug Class Acne Antibiotics Agent Topical Hospital pharmacies Oral Retail Pharmacies Dermatitis Antifungal Agents Monoclonal Antibodies Skin Cancer Others Others Corticosteroids Psoriasis Retinoids Alopecia & Others In this section you will get an understanding of the segmentations which will cover the Canada Dermatology Prescription Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 22 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  23. 2.2.1 Market Segmentation: By Disease Dermatitis market in Canada is a significant component of the overall Dermatology Prescription market ▪ Canada Dermatology Prescription Market Share, By Disease (2022) It has the maximum market share in Canada Dermatology Prescription market with approximately xx% ▪ Alopecia & Others Acne Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Psoriasis In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Dermatitis Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Skin Cancer, Illustrative Illustrative 23 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  24. 2.2.2 Market Segmentation: By Drug Class Monoclonal Antibodies market in Canada is a significant component of the overall Dermatology Prescription market ▪ Canada Dermatology Prescription Market Share, By Drug Class (2022) It has the maximum market share in Canada Dermatology Prescription market with approximately xx% ▪ Antifungal Agents Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Monoclonal Antibodies Antibiotics Agent In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Retinoids, Corticosteroids Illustrative Illustrative 24 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  25. 2.2.3 Market Segmentation: By Route of Administration Canada Dermatology Prescription Market Share, By Route of Administration (2022) Topical Route of Administration has the maximum market share in Canada Dermatology Prescription market with approximately xx% ▪ Others Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Topical Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Oral Illustrative Illustrative 25 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  26. 2.2.4 Market Segmentation: By Distribution Channels Canada Dermatology Prescription Market Share, By Distribution Channels (2022) Retail pharmacies has the maximum market share in Canada Dermatology Prescription market with approximately xx% ▪ Hospital pharmacies Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Retail pharmacies Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Others Illustrative Illustrative 26 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  27. Canada Dermatology Prescription Market Analysis 3. Market Dynamics

  28. 3.1 Market growth drivers 3.1.1 Incidence of skin disease is increasing in Canada with more than 1.3 k new skin disease cases per day is expected to be diagnosed in 2023 Incidence of skin disease is increasing in Canada with more than 1.3 k new skin disease cases per day is expected to be diagnosed in 2023 ▪ Incidence of Skin disease in Canada This is driving the demand for skin disease treatments and creating opportunities for growth in the Canada dermatology Prescription market ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 28 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  29. 3.1 Market growth drivers (continued) 3.1.2 8.7 K+ Canadians are expected to die from skin cancer in 2023 thereby increasing the demand for dermatological products Top countries that are leveraging technology in their fight against Skin Disease Canada has a long history of investing in dermatological research and treatment, and as a result, has become a world leader in the field ▪ Norway Austria IT has a robust healthcare infrastructure, including world- renowned research institutions, hospitals, and clinics, that are dedicated to dermatological treatment and research ▪ Denmark Belgium Spain Italy Netherlands One of the key factors that has allowed Canada to stay ahead in the field of dermatology research and treatment is the high level of investment in dermatology-related research ▪ Sweden Singapore Switzerland Israel In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Australia Canada France Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ United Kingdom China South Korea Germany Japan United States Illustrative Illustrative 29 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  30. 3.1 Market growth drivers (continued) 3.1.3 Increasing awareness of skin health: According to the survey of Canadian Dermatology Association 62% of Canadians are concerned about their skin health thereby rising the need of skin disease products Increasing awareness of skin health in Canada Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 30 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  31. 3.2 Market restraints 3.2.1 In 2022, the average cost of a new skin disease drug was over $100,000 per year 3.2.2 Average cost of developing a new skin disease drug that is ultimately approved by the FDA is over $2.1 Bn 3.2.3 Demand for skin care is expected to increase by 42% by 2025, while the supply of dermatologist is only expected to increase by 28% Skin disease treatments can be very expensive and can lead to financial burden for patients and healthcare systems Cost of skin disease treatment varies depending on the type of skin disease and treatment options Regulatory requirements for skin care treatments can be very stringent, which can slow down the approval process and limit access to new treatments Regulatory bodies, such as Health Canada require extensive clinical trials and safety data before approving new cancer treatments This can be a lengthy and costly process, which can delay the availability of new treatments for patients There is a shortage of dermatologist in Canada , which can limit access to skin disease treatments and create barriers to growth in the dermatology market Dermatologists are physicians who specialize in the diagnosis and treatment of skin diseases With the increasing incidence of skin disease, there is a growing demand for dermatologists However, the supply of dermatologists is not keeping pace with the demand ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative Illustrative 31 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  32. Canada Dermatology Prescription Market Analysis 4. Competitive Landscape

  33. 4.1 Major Market Share Revenue of Major players in Canada Dermatology Prescription Market ($ Mn) Canada cancer market is a highly competitive space, with many companies developing and marketing skin care treatments ▪ Other Some of the top companies in Canada skin care market based on revenue and market share include ▪ Bausch Health Companies Inc.’s is a Canada based multinational pharmaceutical company that develops, manufactures, and markets a wide range of prescription drugs, over-the-counter medications, and medical devices. ▪ The company had a strong presence in the dermatology market, with a portfolio of products that treat a variety of skin conditions, including acne, psoriasis, and eczema. ▪ XX Illustrative Illustrative 33 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  34. 4.2 Key Company Profile Key Note: 1 Bausch Health Here is the list of top 10 companies which will cover in the final report ▪ 2 Galderma Each company will have slides for ▪ 3 Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Sanofi o o 4 Pfizer o o 5 AbbVie o 6 o Johnson & Johnson o 7 LEO Pharma o 8 Affimed ▪ 9 Dermira ▪ 10 Atara Biotherapeutics Illustrative Illustrative 34 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  35. 4.2.1 Bausch Health Companies Inc. Solutions offered by Bausch Health Companies Inc.'s Founded in: 1959 ▪ Bausch Health Companies Inc. is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of pharmaceutical products, primarily for the eye health and dermatology markets ▪ company's portfolio includes prescription drugs, over-the-counter medications, and medical devices ▪ It has a global presence with operations in more than 50 countries ➢ Pharmaceuticals HQ: Laval, Canada ➢ Direct-to-consumer sales Type: Private ➢ Clinical trials Revenue: $7.4 Bn ➢ Medical education Website: www.bauschhealth.com ➢ Patient Support Recent Activity / Press Coverage In 2023,Bausch Health announced that its Salix Pharmaceuticals subsidiary will present data from XIFAXAN® (Rifaximin) clinical research at EASL's International Liver Congress™ 2023 In 2023,Bausch Health responded to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration In 2023,Bausch Health announced that its Solta Medical subsidiary has received FDA clearance for the first non-surgical, non-invasive treatment for cellulite, Accent Ultra Illustrative Illustrative 35 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  36. 4.2.1 Bausch Health Companies Inc.(continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners Illustrative Illustrative 36 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  37. 4.2.1 Bausch Health Companies Inc. (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel Elecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing additional investigation to ensure clinical validation Once approved, could help healthcare professionals to streamline the journey to diagnosis for more patients ▪ ▪ Collaboration - March, 2023 Lilly ▪ Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021 ▪ GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample ▪ Merger $1.8 Bn March 2021 GenMark Diagnostics GenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden ▪ Illustrative Illustrative 37 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  38. 4.2.1 Bausch Health Companies Inc.(continued) Revenues ($Bn), 2020-2030 According to Bausch Health Companies Inc.'s 2021 financial report, the company had sales of 564 Mn in dermatology market in 2021 ▪ This represents a 3% increase from 2020 ▪ Revenue generated by Bausch Health Companies Inc.’s in 2021 reflects the company's continued growth and success in the healthcare industry ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 1 2 3 4 Illustrative Illustrative 38 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  39. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for Cancer Recent Activity / Press Coverage Drugs Indications Illustrative Illustrative 39 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  40. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners Illustrative Illustrative 40 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  41. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Illustrative Illustrative 41 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  42. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 42 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  43. Canada Dermatology Prescription Market Analysis 5. Reimbursement Scenario

  44. 5.1 Reimbursement Regulation Public Insurance provide health insurance coverage for more than 4 in 10 Canadian The reimbursement scenario in Canada Dermatology Prescription market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: Public Insurance: o Public Insurance is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions o Public Insurance covers many skin care treatments, including chemotherapy, radiation therapy, and some immunotherapies o However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization Private Insurance: o Private insurance coverage for skin care treatments can also vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage ▪ Other Public 1% Other Private 3% Uninsured 8% ▪ Public Insurance 44% Employer-Sponsored 44% Health Insurance Coverage, 2022 Illustrative Illustrative 44 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  45. 5.1 Reimbursement Regulation (continued) Affordable Care Act: Affordable Care Act (ACA) includes provisions to help improve access to skin care treatments by requiring insurers to cover certain preventive services, including cancer screenings, without co-pays or deductibles It also includes protections for people with pre-existing conditions, such as cancer Reimbursement for New Treatments: Reimbursement for new skin care treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage This can create challenges for companies developing and marketing new treatments Value-Based Care: There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics ▪ o o ▪ o o ▪ o o In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative 45 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  46. 5.1 Reimbursement Regulation (continued) Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure 46.0% xx 47.7% xx xx xx 51.0% 51.8% xx Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023  Public healthcare coverage is provided by the government and includes programs like Public Insurance  Public Insurance is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in the Canada healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 46 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  47. 5.2 Reimbursement Process for Diagnosis of Skin Diseases The reimbursement process in the Canada healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost of the service, such as deductibles, co-payments, or co-insurance In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 47 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  48. 5.3 Reimbursement Process for Treatment of Skin Diseases The reimbursement process in the Canada healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: FDA Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Market Authorization Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Private Payers Public Payers Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Health Technology Assessment Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ 1 2 3 Coding Coverage Payment Coding depends on availability code while coverage and payment process decisions are made through an HTA. Illustrative Illustrative 48 A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential

  49. Canada Dermatology Prescription Market Analysis 6. Methodology & Scope

  50. Research Methodology Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive overview of the competitive landscape to help our clients make informed strategic decisions We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material, technical journals, trade magazines, and paid data sources For forecasting, the following parameters are considered: ❑ Market drivers and restraints along with their current and expected impacts ❑ Technological scenario and expected developments ❑ End use industry trends and dynamics ❑ Trends in the consumer behavior ❑ Regulatory scenario and expected developments ❑ Current capacity and expected capacity additions up to 2030 We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected market growth rate We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time- sensitive, reflecting the most recent value and volume of the market across regions All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs) Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn) ▪ ▪ ▪ ▪ ▪ ▪ ▪ Illustrative Illustrative

More Related